Phaseline

Targets › HIF2A

HIF2A (Endothelial PAS domain-containing protein 1): drug programs, companies and trials

3 programs from 3 companies in 4 trials: 4 Phase 1; Oncology; next expected readout Nov 2026.

Transcription factor involved in the induction of oxygen regulated genes. Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters (By similarity). (UniProt, Q99814)

Open in Phaseline: the race on HIF2A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)MK-3795
HIF-2α inhibitor
HIF2APhase 1ccRCCNov 2026
Jiangsu Hansoh PharmaceuticalHS-10516
HIF-2α inhibitor
HIF2APhase 1Advanced Clear Cell Renal Cell Carcinoma; Von Hippel Lindau-Deficient Clear Cell Renal Cell CarcinomaJul 2027
Orhan Kemal Oz[18F]PT2385
HIF2α PET imaging agent
HIF2APhase 1Renal Cell CarcinomaAug 2027

Conditions

Renal Cell Carcinoma (1) Advanced Clear Cell Renal Cell Carcinoma (1) Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma (1) ccRCC (1)

Modalities

small molecule (2), mixed (1)

Companies

Orhan Kemal Oz (1) Jiangsu Hansoh Pharmaceutical (1) Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.